Tempest Therapeutics has exercised its option to license Senlang’s CD7-targeted lentiviral in vivo CAR-T platform, gaining exclusive global rights outside China. This follows encouraging preliminary Phase 1 results from their lead BCMA/GPRC5D dual-targeting CAR-T candidate for relapsed or refractory multiple myeloma, showing promising clinical activity in heavily pretreated patients. The license expands Tempest’s capabilities to develop immune reset therapies for cancer and autoimmune diseases, with detailed trial results expected at a major scientific conference.
Tempest Therapeutics' licensing move comes as 69 of 150 Health-sector US stocks on Pluang rose while 74 fell today. For readers following health stocks, here is Pluang's market snapshot as of Nov 11, 2026 20:11 WIB: Alcon AG (ALC) traded at USD 71.61 with a 1-day change of -3.31% and 100% buy order activity, Butterfly Network Inc. (BFLY) at USD 6.70 up 2.92%, and MiniMed Group Inc. (MMED) at USD 17.81 up 2.59%. Typical hold times ranged from 15 to 72 days.
RUM Group Inc. reported a record quarterly revenue of $96.6 million for Q3 2026, a 290% increase year-over-year, surpassing expectations. Despite this, earnings per share were -$0.19, missing the estimate of -$0.11. The company achieved its first pro...
The 2026 Vertex CompOps™ Index reveals that just 16% of enterprises regularly discuss indirect tax at the board level, while 43% only address it when issues arise. Companies with board-level focus on indirect tax are four times less likely to have er...
Richtech Robotics announced its Intelligent Cleaning System at ISSA Show North America 2026, which integrates autonomous cleaning robots with CCTV cameras to enable proactive, targeted cleaning. This system uses real-time data to optimize cleaning ta...
Blue Gold Limited is reducing operating costs and restructuring its balance sheet to address financial obligations and comply with Nasdaq listing requirements. The company is cutting headcount, streamlining operations, and exploring creditor arrangem...
Longevity Health Holdings announced its Board is exploring strategic alternatives for its bio-aesthetic and therapeutic businesses to maximize stakeholder value. Options under consideration include mergers, sales, licensing, or partnerships. This mov...
